Short-term Effects of Acetylcholinesterase Inhibitor Treatment on EEG and Memory Performance in Alzheimer Patients: An Open, Controlled Trial

Pharmacopsychiatry

Volumn 36, Issue 6, 2003, Pages 304-308

  Brassen, S ^a   Adler, G ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Acetylcholine; Acetylcholinesterase inhibitor; Alzheimer's dementia; EEG; Short term Memory

Indexed keywords

CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; DONEPEZIL; INDAN DERIVATIVE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC TRANSMISSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; MALE; MEMORY; MEMORY DISORDER; MENTAL PERFORMANCE; OPEN STUDY; PRIORITY JOURNAL; PSYCHOTHERAPY; RATING SCALE; SCORING SYSTEM; SHORT TERM MEMORY; STATISTICAL SIGNIFICANCE; THETA RHYTHM; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CARBAMATES; CHOLINESTERASE INHIBITORS; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; INDANS; MALE; MEMORY; MEMORY DISORDERS; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; THETA RHYTHM; TIME FACTORS; TREATMENT OUTCOME;

EID: 0345742592     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-45118     Document Type: Article

References (46)

1. Adler G, Brassen S. Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients. Neuropsychobiology 2001; 43: 273-276
2. Agnoli A, Martucci N, Manna V, Conti L, Fioravanti M. Effect of cholinergic and anticholinergic drugs on short-term memory in Alzheimer's dementia: a neuropsychological and computerized electroencephalographic study. Clin Neuropharmacol 1983; 6: 311-323
3. Alhainen K, Riekkinen PJ. Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurol Scan 1993; 149(Suppl.): 16-21
4. Almkvist O. Neuropsychological features of early Alzheimer's disease: preclinical and clinical stages. Acta Neurol Scand Suppl 1996; 165: 63-71
5. Barker A, Jones R, Simpson P, Wesnes K. Scopolamine-induced cognitive impairments as a predictor of cognitive decline in healthy elderly volunteers. Int J Geriatr Psychiat 1995; 10: 1059-1062
6. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 17: 408-417
7. Brenner RP, Ulrich RF, Spiker DG, Scabassi RJ, Reynolds CF, Marin RS, Boller F. Computerized EEG spectral analysis in elderly normal, demented and depressed subjects. Electroencephalogr Clin Neurophysiol 1986; 64: 483-492
8. Breslau J, Starr A, Sicotte N, Buchsbaum MS. Topographic EEG changes with normal aging and SDAT. Electroencephalogr Clin Neurophysiol 1989; 72: 281-289
9. Broks P, Preston GC, Traub M, Poppleton P, Ward C, Stahl SM. Modelling dementia: Effects of scopolamine on memory and attention. Neuropsychologia 1988; 26: 685-700
10. Chiaramonti R, Muscas GC, Paganini M, Müller TJ, Fallgatter AJ, Versari A, Strik WK. Correlations of topographical EEG feature with clinical severity in mild and moderate dementia of Alzheimer type. Neuropsychobiology 1997; 36: 153-158
11. Coben LA, Danzinger W, Storandt M. A longitudinal EEG study of mild senile dementia of Alzheimer type: changes at 1 year and at 2.5 years. Electroencephalogr Clin Neurophysiol 1985; 61: 101-112
12. Coben LA, Danzinger WL, Berg L. Frequency analysis of the resting awake EEG in mild senile dementia of Alzheimer type. Electropencephalogr Clin Neurophysiol 1983; 55: 372-380
13. Davies P, Maloney JF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; ii: 403
14. Dierks T, Perisic I, Frölich L, Ihl R, Maurer K. Topographie of the Quantitative Electroencephalogram in Dementia of the Alzheimer Type: Relation to Severity of Dementia. Psychiatry Res: Neuroimaging 1991; 40: 181-194
15. Duffy FH, Albert MS, McAnulty G. Brain electrical activity in patients with presenile and senile dementia of the Alzheimer type. Ann Neurol 1984; 16: 439-448
16. Farlow MR, Evans RM. Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology 1998; 51(Suppl.1): S36-44
17. Förstl H, Besthorn C, Sattel H, Zerfass R, Geiger-Kabisch C, Schreiter-Gasser U, Hentschel F. Volumetrische Hirnveränderungen und quantitatives EEG bei normalem Altern und Alzheimer-Demenz. Nervenarzt 1996; 67: 53-61
18. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental-State". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198
19. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypthesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiat 1999; 66: 137-147
20. Gatterer G. Alters-Konzentrations-Test (AKT). Göttingen: Hogrefe, 1990
21. Giannitrapani D, Collins J, Vassiliadis D. The EEG spectra of Alzheimer's disease. Int J Psychophysiol 1991; 10: 259-269
22. Gustafson L, Edvinsson L, Dahlgren N, Hagberg B, Risberg J, Rosén I, Fernö H. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow measurement, and EEG. Psychopharmacology 1987; 93: 31-35
23. Gutzmann H, Kuhl KP, Hadler D, Rapp MA. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double blind parallel-group multicenter study. Pharmacopsychiatry 2002; 35: 12-18
24. Heinze M, Andreae D, Grohmann R. Rivastigmin and impaired motor function. Pharmacopsychiatry 2002; 35: 79-80
25. Ihl R, Dierks T, Martin EM, Frölich L, Maurer K. Topography of the maximum of the amplitude of EEG frequency bands in dementia of the Alzheimer type. Biol Psychiat 1996; 39: 319-325
26. Jelic V, Dierks T, Amberla K, Almkvist O, Winblad B, Nordberg A. Longitudinal changes in quantitative EEG during long-term tacrine treatment of patients with Alzheimer's disease. Neurosci Lett 1998; 254: 85-88
27. Jelic V, Shigeta M, Julin P, Ove Almkvist, Winblad B, Wahlund L-O. Quantitative electroencephalography power and coherence in Alzheimer's disease and mild cognitive impairment. Dementia 1996; 7: 314-323
28. Katznelson RD. EEG recording, electrode placement, and aspects of generator localization. In: Nuñez PL (ed). Electrical fields of the brain New York: Oxford University Press, 1981
29. Kikuchi M, Wada Y, Nanbu Y, Nakajima A, Tachibana H, Takeda T, Hashimoto T. EEG changes following scopolamine administration in healthy subjects. Neuropsychobiology 1999; 39: 219-226
30. Knopman DS, Knapp MJ, Grason SI, Davis CS. The clinician interview-based impression (CIBI): A clinician's global change rating scale in Alzheimer's disease. Neurology 1995; 44: 2315-2321
31. Leuchter AF, Spar JE, Walter DO, Weiner H. Electroencephalographic spectra and coherence in the diagnosis of Alzheimer's-type and multi-infarct dementia. A pilot study. Arch Gen Psychiat 1987; 44(11): 993-998
32. Little JT, Johnson DN, Minichiello M, Weingartner H, Sunderland T. Combined nicotinic and muscarinic blockade in elderly normal volunteers: Cognitive, behavioral, and physiologic responses. Neuropsychopharmacology 1998; 19: 60-69
33. Minthon L, Gustafson L, Dalfelt G, Hagberg B, Nilsson K, Risberg J, Rosén I, Seiving B, Wendt PE. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG. Dementia 1993; 4: 32-42
34. d'Onofrio F, Salvia S, Petretta V, Bonavita V, Rodriguez G, Tedeschi G. Quantified-EEG in normal aging and dementias. Acta Neurol Scand 1996; 93: 336-345
35. Penttila M, Partanen VJ, Soininen H, Riekkinen PJ. Quantitative analysis of occipital EEG in different stages of Alzheimer's disease. Electroencephalogr Clin Neurophysiol 1985; 60: 1-6
36. Reisberg B, Ferris SH, De Leon MJ, Crook T. The global deterioration scale of assessment of primary degenerative dementia. Am J Psychiat 1982; 139: 1136-1139
37. Riekkinen P, Buzsaki G, Riekkinen Jr P, Soininen H, Partanen J. The cholinergic system and EEG slow waves. Electroencephalogr Clin Neurophysiol 1991; 78: 89-96
38. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international, randomised controlled trial. BMJ 1999; 318: 633-640
39. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-1364
40. Sannita WG, Maggi L, Rosadini G. Effects of scopolamine (0.25-0.75 mg i.m.) on the quantitative EEG and neuropsychological status of healthy volunteers. Neuropsychobiology 1987; 17: 199-205
41. Semlitsch HV, Anderer P, Saletu B, Schuster P, Presslich O. A solution for reliable and valid reduction of ocular artifacts to the P300 ERP. Psychophysiology 1986; 23: 695-703
42. Szelies B. Brain mapping zur Darstellung altersabhängiger Veränderungen in Abgrenzung von Demenz. Nervenarzt 1992; 63: 609-618
43. Szelies B, Grond M, Herholz K, Kessler J, Heiss WD. Quantitative EEG mapping and PET in Alzheimer's disease. J Neurol Sci 1992; 110: 46-56
44. Vitaliano PP, Russo J, Breen AR, Vitiello MV, Prinz PN. Functional decline in early stages of Alzheimer's disease. Psychol Aging 1986; 1(1): 41-46
45. Wechsler D. WMS-R Wechsler Memory Scale - Revised. Manual. San Antonio: The Psychological Corporation Harcourt Brace Jovanovich, Inc. 1987
46. Zaudig M, Mittelhammer J, Hiller W, Pauls A, Thora C, Morinigo A, Mombour W. SIDAM - A structured interview for the diagnosis of dementia of the Alzheimer type, multi-infarct dementia and dementias of other aetiology according to ICD-10 and DSM-III-R. Psychol Med 1991; 21(1): 225-236